Elicitation of potent SARS-CoV-2 neutralizing antibody responses through immunization with a versatile adenovirus-inspired multimerization platform

Virus-like particles (VLPs) are highly suited platforms for protein-based vaccines. In the present work, we adapted a previously designed non-infectious adenovirus-inspired 60-mer dodecahedric VLP (ADDomer) to display a multimeric array of large antigens through a SpyTag/SpyCatcher system. To valida...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Molecular therapy 2022-05, Vol.30 (5), p.1913-1925
Hauptverfasser: Chevillard, Christopher, Amen, Axelle, Besson, Solène, Hannani, Dalil, Bally, Isabelle, Dettling, Valentin, Gout, Evelyne, Moreau, Christophe J., Buisson, Marlyse, Gallet, Salomé, Fenel, Daphna, Vassal-Stermann, Emilie, Schoehn, Guy, Poignard, Pascal, Dagher, Marie-Claire, Fender, Pascal
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1925
container_issue 5
container_start_page 1913
container_title Molecular therapy
container_volume 30
creator Chevillard, Christopher
Amen, Axelle
Besson, Solène
Hannani, Dalil
Bally, Isabelle
Dettling, Valentin
Gout, Evelyne
Moreau, Christophe J.
Buisson, Marlyse
Gallet, Salomé
Fenel, Daphna
Vassal-Stermann, Emilie
Schoehn, Guy
Poignard, Pascal
Dagher, Marie-Claire
Fender, Pascal
description Virus-like particles (VLPs) are highly suited platforms for protein-based vaccines. In the present work, we adapted a previously designed non-infectious adenovirus-inspired 60-mer dodecahedric VLP (ADDomer) to display a multimeric array of large antigens through a SpyTag/SpyCatcher system. To validate the platform as a potential COVID-19 vaccine approach, we decorated the newly designed VLP with the glycosylated receptor binding domain (RBD) of SARS-CoV-2. Cryoelectron microscopy structure revealed that up to 60 copies of this antigenic domain could be bound on a single ADDomer particle, with the symmetrical arrangements of a dodecahedron. Mouse immunization with the RBD decorated VLPs already showed a significant specific humoral response following prime vaccination, greatly reinforced by a single boost. Neutralization assays with SARS-CoV-2 spike pseudo-typed virus demonstrated the elicitation of strong neutralization titers, superior to those of COVID-19 convalescent patients. Notably, the presence of pre-existing immunity against the adenoviral-derived particles did not hamper the immune response against the antigen displayed on its surface. This plug and play vaccine platform represents a promising new highly versatile tool to combat emergent pathogens. [Display omitted] In this study, Chevillard and colleagues report a non-infectious adenovirus-inspired self-assembling particle designed to spontaneously and covalently display up to 60 SARS-CoV-2 glycoantigens. Immunization of mice with this pseudoviral mimic generates a strong neutralizing antibody response capable of neutralizing SARS-CoV-2 in the long term. A new tool for pandemic preparedness.
doi_str_mv 10.1016/j.ymthe.2022.02.011
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8828441</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1525001622000946</els_id><sourcerecordid>2628698124</sourcerecordid><originalsourceid>FETCH-LOGICAL-c493t-88fe01d87e8f26e8de6c9a6e09ea63594d0b432dc778a6260989ed419fdd192f3</originalsourceid><addsrcrecordid>eNp9UdGK1DAULaK46-oXCJJH96FjkrZp8qAwDKu7MCC46mvINLfTDG1Sk7Qy-xv-sJmd3UF9EC7kcnPuOZx7suw1wQuCCXu3W-yH2MGCYkoXOBUhT7JzUtEqx5iWT089YWfZixB2qSOVYM-zs6IiFeFlcZ79uupNY6KKxlnkWjS6CDai2-WX23zlvucUWZiiV725M3aLlI1m4_QeeQijswECip1307ZDZhgma-6OTD9N7JBCM_iQBj0gpcG62fgp5MaG0XjQaJj6aAbwj0tjr2Lr_PAye9aqPsCrh_ci-_bx6uvqOl9__nSzWq7zphRFzDlvARPNa-AtZcA1sEYoBliAYkUlSo03ZUF1U9dcMcqw4AJ0SUSrNRG0LS6yD0fecdoMoJtkPBmVozeD8nvplJF__1jTya2bJeeUlyVJBJdHgu6ftevlWh5muKgrxkQ9H7BvH8S8-zFBiHIwoYG-VxbcFCRllDPBCS0TtDhCG-9C8NCeuAmWh-jlTt5HLw_RS5yKHATe_OnmtPOYdQK8PwIg3XQ24GVoDNgGdEqjiVI781-B36OOxeI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2628698124</pqid></control><display><type>article</type><title>Elicitation of potent SARS-CoV-2 neutralizing antibody responses through immunization with a versatile adenovirus-inspired multimerization platform</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Chevillard, Christopher ; Amen, Axelle ; Besson, Solène ; Hannani, Dalil ; Bally, Isabelle ; Dettling, Valentin ; Gout, Evelyne ; Moreau, Christophe J. ; Buisson, Marlyse ; Gallet, Salomé ; Fenel, Daphna ; Vassal-Stermann, Emilie ; Schoehn, Guy ; Poignard, Pascal ; Dagher, Marie-Claire ; Fender, Pascal</creator><creatorcontrib>Chevillard, Christopher ; Amen, Axelle ; Besson, Solène ; Hannani, Dalil ; Bally, Isabelle ; Dettling, Valentin ; Gout, Evelyne ; Moreau, Christophe J. ; Buisson, Marlyse ; Gallet, Salomé ; Fenel, Daphna ; Vassal-Stermann, Emilie ; Schoehn, Guy ; Poignard, Pascal ; Dagher, Marie-Claire ; Fender, Pascal</creatorcontrib><description>Virus-like particles (VLPs) are highly suited platforms for protein-based vaccines. In the present work, we adapted a previously designed non-infectious adenovirus-inspired 60-mer dodecahedric VLP (ADDomer) to display a multimeric array of large antigens through a SpyTag/SpyCatcher system. To validate the platform as a potential COVID-19 vaccine approach, we decorated the newly designed VLP with the glycosylated receptor binding domain (RBD) of SARS-CoV-2. Cryoelectron microscopy structure revealed that up to 60 copies of this antigenic domain could be bound on a single ADDomer particle, with the symmetrical arrangements of a dodecahedron. Mouse immunization with the RBD decorated VLPs already showed a significant specific humoral response following prime vaccination, greatly reinforced by a single boost. Neutralization assays with SARS-CoV-2 spike pseudo-typed virus demonstrated the elicitation of strong neutralization titers, superior to those of COVID-19 convalescent patients. Notably, the presence of pre-existing immunity against the adenoviral-derived particles did not hamper the immune response against the antigen displayed on its surface. This plug and play vaccine platform represents a promising new highly versatile tool to combat emergent pathogens. [Display omitted] In this study, Chevillard and colleagues report a non-infectious adenovirus-inspired self-assembling particle designed to spontaneously and covalently display up to 60 SARS-CoV-2 glycoantigens. Immunization of mice with this pseudoviral mimic generates a strong neutralizing antibody response capable of neutralizing SARS-CoV-2 in the long term. A new tool for pandemic preparedness.</description><identifier>ISSN: 1525-0016</identifier><identifier>EISSN: 1525-0024</identifier><identifier>DOI: 10.1016/j.ymthe.2022.02.011</identifier><identifier>PMID: 35151843</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adenoviridae ; Adenoviridae - genetics ; Adenovirus ; Animals ; Antibodies, Neutralizing ; Antibodies, Viral ; Antigen display ; Biochemistry, Molecular Biology ; COVID-19 ; COVID-19 - prevention &amp; control ; COVID-19 Vaccines ; Cryoelectron Microscopy ; Humans ; Life Sciences ; Mice ; Neutralizing antibodies ; Original ; Receptor-binding domain ; SARS-CoV-2 ; Structural Biology ; Vaccination ; Vaccine platform ; Virus-like particle</subject><ispartof>Molecular therapy, 2022-05, Vol.30 (5), p.1913-1925</ispartof><rights>2022 The Author(s)</rights><rights>Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><rights>2022 The Author(s) 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c493t-88fe01d87e8f26e8de6c9a6e09ea63594d0b432dc778a6260989ed419fdd192f3</citedby><cites>FETCH-LOGICAL-c493t-88fe01d87e8f26e8de6c9a6e09ea63594d0b432dc778a6260989ed419fdd192f3</cites><orcidid>0000-0001-5097-1401 ; 0000-0002-5463-9593 ; 0000-0002-8486-4935 ; 0000-0002-8315-6080</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8828441/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8828441/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,725,778,782,883,27907,27908,53774,53776</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35151843$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-03756697$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Chevillard, Christopher</creatorcontrib><creatorcontrib>Amen, Axelle</creatorcontrib><creatorcontrib>Besson, Solène</creatorcontrib><creatorcontrib>Hannani, Dalil</creatorcontrib><creatorcontrib>Bally, Isabelle</creatorcontrib><creatorcontrib>Dettling, Valentin</creatorcontrib><creatorcontrib>Gout, Evelyne</creatorcontrib><creatorcontrib>Moreau, Christophe J.</creatorcontrib><creatorcontrib>Buisson, Marlyse</creatorcontrib><creatorcontrib>Gallet, Salomé</creatorcontrib><creatorcontrib>Fenel, Daphna</creatorcontrib><creatorcontrib>Vassal-Stermann, Emilie</creatorcontrib><creatorcontrib>Schoehn, Guy</creatorcontrib><creatorcontrib>Poignard, Pascal</creatorcontrib><creatorcontrib>Dagher, Marie-Claire</creatorcontrib><creatorcontrib>Fender, Pascal</creatorcontrib><title>Elicitation of potent SARS-CoV-2 neutralizing antibody responses through immunization with a versatile adenovirus-inspired multimerization platform</title><title>Molecular therapy</title><addtitle>Mol Ther</addtitle><description>Virus-like particles (VLPs) are highly suited platforms for protein-based vaccines. In the present work, we adapted a previously designed non-infectious adenovirus-inspired 60-mer dodecahedric VLP (ADDomer) to display a multimeric array of large antigens through a SpyTag/SpyCatcher system. To validate the platform as a potential COVID-19 vaccine approach, we decorated the newly designed VLP with the glycosylated receptor binding domain (RBD) of SARS-CoV-2. Cryoelectron microscopy structure revealed that up to 60 copies of this antigenic domain could be bound on a single ADDomer particle, with the symmetrical arrangements of a dodecahedron. Mouse immunization with the RBD decorated VLPs already showed a significant specific humoral response following prime vaccination, greatly reinforced by a single boost. Neutralization assays with SARS-CoV-2 spike pseudo-typed virus demonstrated the elicitation of strong neutralization titers, superior to those of COVID-19 convalescent patients. Notably, the presence of pre-existing immunity against the adenoviral-derived particles did not hamper the immune response against the antigen displayed on its surface. This plug and play vaccine platform represents a promising new highly versatile tool to combat emergent pathogens. [Display omitted] In this study, Chevillard and colleagues report a non-infectious adenovirus-inspired self-assembling particle designed to spontaneously and covalently display up to 60 SARS-CoV-2 glycoantigens. Immunization of mice with this pseudoviral mimic generates a strong neutralizing antibody response capable of neutralizing SARS-CoV-2 in the long term. A new tool for pandemic preparedness.</description><subject>Adenoviridae</subject><subject>Adenoviridae - genetics</subject><subject>Adenovirus</subject><subject>Animals</subject><subject>Antibodies, Neutralizing</subject><subject>Antibodies, Viral</subject><subject>Antigen display</subject><subject>Biochemistry, Molecular Biology</subject><subject>COVID-19</subject><subject>COVID-19 - prevention &amp; control</subject><subject>COVID-19 Vaccines</subject><subject>Cryoelectron Microscopy</subject><subject>Humans</subject><subject>Life Sciences</subject><subject>Mice</subject><subject>Neutralizing antibodies</subject><subject>Original</subject><subject>Receptor-binding domain</subject><subject>SARS-CoV-2</subject><subject>Structural Biology</subject><subject>Vaccination</subject><subject>Vaccine platform</subject><subject>Virus-like particle</subject><issn>1525-0016</issn><issn>1525-0024</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UdGK1DAULaK46-oXCJJH96FjkrZp8qAwDKu7MCC46mvINLfTDG1Sk7Qy-xv-sJmd3UF9EC7kcnPuOZx7suw1wQuCCXu3W-yH2MGCYkoXOBUhT7JzUtEqx5iWT089YWfZixB2qSOVYM-zs6IiFeFlcZ79uupNY6KKxlnkWjS6CDai2-WX23zlvucUWZiiV725M3aLlI1m4_QeeQijswECip1307ZDZhgma-6OTD9N7JBCM_iQBj0gpcG62fgp5MaG0XjQaJj6aAbwj0tjr2Lr_PAye9aqPsCrh_ci-_bx6uvqOl9__nSzWq7zphRFzDlvARPNa-AtZcA1sEYoBliAYkUlSo03ZUF1U9dcMcqw4AJ0SUSrNRG0LS6yD0fecdoMoJtkPBmVozeD8nvplJF__1jTya2bJeeUlyVJBJdHgu6ftevlWh5muKgrxkQ9H7BvH8S8-zFBiHIwoYG-VxbcFCRllDPBCS0TtDhCG-9C8NCeuAmWh-jlTt5HLw_RS5yKHATe_OnmtPOYdQK8PwIg3XQ24GVoDNgGdEqjiVI781-B36OOxeI</recordid><startdate>20220504</startdate><enddate>20220504</enddate><creator>Chevillard, Christopher</creator><creator>Amen, Axelle</creator><creator>Besson, Solène</creator><creator>Hannani, Dalil</creator><creator>Bally, Isabelle</creator><creator>Dettling, Valentin</creator><creator>Gout, Evelyne</creator><creator>Moreau, Christophe J.</creator><creator>Buisson, Marlyse</creator><creator>Gallet, Salomé</creator><creator>Fenel, Daphna</creator><creator>Vassal-Stermann, Emilie</creator><creator>Schoehn, Guy</creator><creator>Poignard, Pascal</creator><creator>Dagher, Marie-Claire</creator><creator>Fender, Pascal</creator><general>Elsevier Inc</general><general>Cell Press</general><general>American Society of Gene &amp; Cell Therapy</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-5097-1401</orcidid><orcidid>https://orcid.org/0000-0002-5463-9593</orcidid><orcidid>https://orcid.org/0000-0002-8486-4935</orcidid><orcidid>https://orcid.org/0000-0002-8315-6080</orcidid></search><sort><creationdate>20220504</creationdate><title>Elicitation of potent SARS-CoV-2 neutralizing antibody responses through immunization with a versatile adenovirus-inspired multimerization platform</title><author>Chevillard, Christopher ; Amen, Axelle ; Besson, Solène ; Hannani, Dalil ; Bally, Isabelle ; Dettling, Valentin ; Gout, Evelyne ; Moreau, Christophe J. ; Buisson, Marlyse ; Gallet, Salomé ; Fenel, Daphna ; Vassal-Stermann, Emilie ; Schoehn, Guy ; Poignard, Pascal ; Dagher, Marie-Claire ; Fender, Pascal</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c493t-88fe01d87e8f26e8de6c9a6e09ea63594d0b432dc778a6260989ed419fdd192f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Adenoviridae</topic><topic>Adenoviridae - genetics</topic><topic>Adenovirus</topic><topic>Animals</topic><topic>Antibodies, Neutralizing</topic><topic>Antibodies, Viral</topic><topic>Antigen display</topic><topic>Biochemistry, Molecular Biology</topic><topic>COVID-19</topic><topic>COVID-19 - prevention &amp; control</topic><topic>COVID-19 Vaccines</topic><topic>Cryoelectron Microscopy</topic><topic>Humans</topic><topic>Life Sciences</topic><topic>Mice</topic><topic>Neutralizing antibodies</topic><topic>Original</topic><topic>Receptor-binding domain</topic><topic>SARS-CoV-2</topic><topic>Structural Biology</topic><topic>Vaccination</topic><topic>Vaccine platform</topic><topic>Virus-like particle</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chevillard, Christopher</creatorcontrib><creatorcontrib>Amen, Axelle</creatorcontrib><creatorcontrib>Besson, Solène</creatorcontrib><creatorcontrib>Hannani, Dalil</creatorcontrib><creatorcontrib>Bally, Isabelle</creatorcontrib><creatorcontrib>Dettling, Valentin</creatorcontrib><creatorcontrib>Gout, Evelyne</creatorcontrib><creatorcontrib>Moreau, Christophe J.</creatorcontrib><creatorcontrib>Buisson, Marlyse</creatorcontrib><creatorcontrib>Gallet, Salomé</creatorcontrib><creatorcontrib>Fenel, Daphna</creatorcontrib><creatorcontrib>Vassal-Stermann, Emilie</creatorcontrib><creatorcontrib>Schoehn, Guy</creatorcontrib><creatorcontrib>Poignard, Pascal</creatorcontrib><creatorcontrib>Dagher, Marie-Claire</creatorcontrib><creatorcontrib>Fender, Pascal</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Molecular therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chevillard, Christopher</au><au>Amen, Axelle</au><au>Besson, Solène</au><au>Hannani, Dalil</au><au>Bally, Isabelle</au><au>Dettling, Valentin</au><au>Gout, Evelyne</au><au>Moreau, Christophe J.</au><au>Buisson, Marlyse</au><au>Gallet, Salomé</au><au>Fenel, Daphna</au><au>Vassal-Stermann, Emilie</au><au>Schoehn, Guy</au><au>Poignard, Pascal</au><au>Dagher, Marie-Claire</au><au>Fender, Pascal</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Elicitation of potent SARS-CoV-2 neutralizing antibody responses through immunization with a versatile adenovirus-inspired multimerization platform</atitle><jtitle>Molecular therapy</jtitle><addtitle>Mol Ther</addtitle><date>2022-05-04</date><risdate>2022</risdate><volume>30</volume><issue>5</issue><spage>1913</spage><epage>1925</epage><pages>1913-1925</pages><issn>1525-0016</issn><eissn>1525-0024</eissn><abstract>Virus-like particles (VLPs) are highly suited platforms for protein-based vaccines. In the present work, we adapted a previously designed non-infectious adenovirus-inspired 60-mer dodecahedric VLP (ADDomer) to display a multimeric array of large antigens through a SpyTag/SpyCatcher system. To validate the platform as a potential COVID-19 vaccine approach, we decorated the newly designed VLP with the glycosylated receptor binding domain (RBD) of SARS-CoV-2. Cryoelectron microscopy structure revealed that up to 60 copies of this antigenic domain could be bound on a single ADDomer particle, with the symmetrical arrangements of a dodecahedron. Mouse immunization with the RBD decorated VLPs already showed a significant specific humoral response following prime vaccination, greatly reinforced by a single boost. Neutralization assays with SARS-CoV-2 spike pseudo-typed virus demonstrated the elicitation of strong neutralization titers, superior to those of COVID-19 convalescent patients. Notably, the presence of pre-existing immunity against the adenoviral-derived particles did not hamper the immune response against the antigen displayed on its surface. This plug and play vaccine platform represents a promising new highly versatile tool to combat emergent pathogens. [Display omitted] In this study, Chevillard and colleagues report a non-infectious adenovirus-inspired self-assembling particle designed to spontaneously and covalently display up to 60 SARS-CoV-2 glycoantigens. Immunization of mice with this pseudoviral mimic generates a strong neutralizing antibody response capable of neutralizing SARS-CoV-2 in the long term. A new tool for pandemic preparedness.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>35151843</pmid><doi>10.1016/j.ymthe.2022.02.011</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0001-5097-1401</orcidid><orcidid>https://orcid.org/0000-0002-5463-9593</orcidid><orcidid>https://orcid.org/0000-0002-8486-4935</orcidid><orcidid>https://orcid.org/0000-0002-8315-6080</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1525-0016
ispartof Molecular therapy, 2022-05, Vol.30 (5), p.1913-1925
issn 1525-0016
1525-0024
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8828441
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection
subjects Adenoviridae
Adenoviridae - genetics
Adenovirus
Animals
Antibodies, Neutralizing
Antibodies, Viral
Antigen display
Biochemistry, Molecular Biology
COVID-19
COVID-19 - prevention & control
COVID-19 Vaccines
Cryoelectron Microscopy
Humans
Life Sciences
Mice
Neutralizing antibodies
Original
Receptor-binding domain
SARS-CoV-2
Structural Biology
Vaccination
Vaccine platform
Virus-like particle
title Elicitation of potent SARS-CoV-2 neutralizing antibody responses through immunization with a versatile adenovirus-inspired multimerization platform
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T13%3A27%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Elicitation%20of%20potent%20SARS-CoV-2%20neutralizing%20antibody%20responses%20through%20immunization%20with%20a%20versatile%20adenovirus-inspired%20multimerization%20platform&rft.jtitle=Molecular%20therapy&rft.au=Chevillard,%20Christopher&rft.date=2022-05-04&rft.volume=30&rft.issue=5&rft.spage=1913&rft.epage=1925&rft.pages=1913-1925&rft.issn=1525-0016&rft.eissn=1525-0024&rft_id=info:doi/10.1016/j.ymthe.2022.02.011&rft_dat=%3Cproquest_pubme%3E2628698124%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2628698124&rft_id=info:pmid/35151843&rft_els_id=S1525001622000946&rfr_iscdi=true